Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.

Raja, Srikumar M

Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. [electronic resource] - Cancer biology & therapy Jan 2011 - 263-76 p. digital

Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

1555-8576

10.4161/cbt.11.2.13959 doi


Animals
Antibodies, Monoclonal--pharmacology
Antibodies, Monoclonal, Humanized
Antineoplastic Agents--pharmacology
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Breast Neoplasms--drug therapy
Cell Line, Tumor
Cell Survival--drug effects
Dose-Response Relationship, Drug
Drug Evaluation, Preclinical
Drug Synergism
Female
HSP90 Heat-Shock Proteins--antagonists & inhibitors
Humans
Inhibitory Concentration 50
Lapatinib
Mice
Mice, SCID
Pentacyclic Triterpenes
Quinazolines--pharmacology
Receptor, ErbB-2--antagonists & inhibitors
Signal Transduction
Trastuzumab
Triterpenes--administration & dosage
Tumor Burden--drug effects
Xenograft Model Antitumor Assays--methods